Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug duo aims to control lymphoma without chemo

NCT ID NCT03198026

Ongoing Disease control Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial is testing two drugs, obinutuzumab and ibrutinib, as the first treatment for people with indolent non-Hodgkin's lymphoma, a slow-growing blood cancer. The goal is to see how many patients respond to the combination. The study involves 30 participants and is no longer recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
obinutuzumab and ibrutinib
What this could lead to
If this works, it could offer a new first-line treatment option that helps control indolent non-Hodgkin's lymphoma without needing chemotherapy.
What could go wrong
This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. The combination may cause side effects like infections or bleeding, and it is not a cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANN ABOR STAGE III B-CELL NON-HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aggressive B-cell non-Hodgkin lymphoma B-cell non-Hodgkin lymphoma follicular lymphoma indolent B-cell non-Hodgkin lymphoma MALT lymphoma nodal marginal zone B-cell lymphoma non-Hodgkin lymphoma splenic marginal zone lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANN ABOR STAGE III B-CELL NON-HODGKIN LYMPHOMA ANN ARBOR STAGE II EXTRANODAL MARGINAL ZONE LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE ANN ARBOR STAGE II FOLLICULAR LYMPHOMA ANN ARBOR STAGE II NODAL MARGINAL ZONE LYMPHOMA ANN ARBOR STAGE III EXTRANODAL MARGINAL ZONE LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE ANN ARBOR STAGE III FOLLICULAR LYMPHOMA ANN ARBOR STAGE III NODAL MARGINAL ZONE LYMPHOMA ANN ARBOR STAGE IV B-CELL NON-HODGKIN LYMPHOMA ANN ARBOR STAGE IV EXTRANODAL MARGINAL ZONE LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE ANN ARBOR STAGE IV FOLLICULAR LYMPHOMA ANN ARBOR STAGE IV NODAL MARGINAL ZONE LYMPHOMA GRADE 1 FOLLICULAR LYMPHOMA GRADE 2 FOLLICULAR LYMPHOMA GRADE 3A FOLLICULAR LYMPHOMA INDOLENT NON-HODGKIN LYMPHOMA NON-HODGKIN'S LYMPHOMA STAGE II SPLENIC MARGINAL ZONE LYMPHOMA STAGE III SPLENIC MARGINAL ZONE LYMPHOMA STAGE IV SPLENIC MARGINAL ZONE LYMPHOMA

Contacts and locations

Locations

  • Sidney Kimmel Cancer Center at Thomas Jefferson University

    Philadelphia, Pennsylvania, 19107, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.